New York, United States - Protheragen has launched GeniusAb™, a fully human single-domain antibody platform to produce high quality and customized antibodies for research, diagnostic and therapeutic ...

CStone will receive upfront, regulatory and commercial milestone payments, and book revenue from SteinCares through the supply of sugemalimab in 10 Latin American (LATAM) countries. This marks ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

Tiziana Life Sciences Ltd., which is developing the intranasal fully human anti-CD3 monoclonal antibody foralumab for neurological indications, has reported results from studies using a nasal anti-CD3 ...

Biocytogen (HKEX: 02315), a global biotech company dedicated to discovering and developing novel antibody therapeutics, announced the licensing of its fully human antibodies to SOTIO Biotech ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

Tiziana Life Sciences announces positive results from studies using nasal anti-CD3 mAb in traumatic spinal cord injury: New York Saturday, January 25, 2025, 13:00 Hrs [IST] Tizian ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its ...

A new technology developed at MIT enables scientists to label proteins across millions of individual cells in fully intact 3D ...